目的: 研究比较在晚期卵巢癌中紫杉醇联合奈达铂同步恩度治疗与单纯紫杉醇联合奈达铂的疗效
和不良反应。方法: 36 例经病理学证实的中晚期卵巢癌病人，随机分为两组: 试验组( 恩度静脉滴注+紫杉醇联
合奈达铂化疗) 18 例，对照组( 单纯紫杉醇联合奈达铂化疗) 18 例。比较治疗前、治疗2 周期、治疗4 周期后血清
CA 125、肿瘤大小变化，并观察两组不良反应的发生率，评价临床疗效和安全性。结果: 两组均完成治疗，2 周期
后恩度组的有效率为38．9%，对照组有效率为22．2%，两组之间具有统计学差异( P＜0．05) ，4 周期后有效率分别
为50．2%和30．1%，差异亦有统计学意义。对两组不良反应情况进行比较，主要为骨髓抑制、消化道反应为主，两
组差异无统计学意义( P＞0．05) ，心脏毒性，试验组略多于对照组，但差异无统计学意义。结论: 恩度联合TP 方
案治疗中晚期卵巢癌疗效确切，不良反应轻，值得推广应用。

Objective: To study the efficacy and safety of rh－endostain( endostar) combined with
TP regimen( paclitaxel plus nedaplatin) on patients with advanced ovarian cancer．Methods: A retrospective
analysis of 36 cases of advanced ovarian cancer patients confirmed by histopathology or cytopathology，
were compared， treated from 2012－10 to 2015－05 in our hospital．It was randomly divided into
two groups; one group of 18 cases was given paclitaxel plus nedaplatin combined with rh －endostain
( trial group) ，another of 18 cases was treated only by paclitaxel plus nedaplatin( control group) ． endostar)
combined with TP scheme: endostar 15 mg /d，d 1－14，paclitaxel 135～175 mg /m2，d 1，nedaplatin
60～80 mg /m2 d 1; paclitaxel and nedaplatin scheme: paclitaxel 135 ～ 175 mg /m2，d 1，nedaplatin
60 ～80 mg /m2 d 1; Tumor size were measured before and after two cycles，and after four cycles of treatment
between both group．The incidence of adverse reactions of two groups of observation was collected
in 1months after the end by reviewing the clinical efficacy of CT．Ｒesults: Two groups were completed
the treatment，after 2 cycles，ＲＲ of paclitaxel and nedaplatin combined with endostar group was 38．9%，
ＲＲ of control group was 22．2%，with statistically significant difference between the two groups ( P ＜
0．05) ．While those were 50．2%and 30．1%after four cycles treatment， the efficacy of the paclitaxel and
nedaplatin combined with endostar group was better than the contral group( P＜0．01) ．To compare the
two groups of adverse reactions，mainly for bone marrow transplantation，digestive tract reaction，andcardiovascular
toxicity．All of the difference was no statistically significant( P＞0．05) ．Conclusion: The curative
effect of clinical application of paclitaxel plus nedaplatin combined with endostar in treatment of
advanced ovarian cancer is accurate， less adverse reactions， it is worthy of popularization and application．

Ｒ713．6

 收稿日期: 2017－11－18; 修回日期: 2018－02－27
基金项目: 湖北省教育厅优秀中青年科技创新团队项目( T201510)
作者简介: 余建云( 1981－) ，女，湖北医学院附属人民医院主治医师，医学硕士。
通讯作者: 江良波，副主任医师，硕士研究生导师，E－mail: Lilinjun00417@ 126．com 湖北医学院附属人民医院， 442000